Detailed information for compound 1589953
Basic information
Technical information
- Name: Unnamed compound
- MW: 467.249 | Formula: C17H16BrFN6O4
-
H donors: 1
H acceptors: 6
LogP: 3.43
Rotable bonds: 6
Rule of 5 violations (Lipinski): 1 - SMILES: OC(=O)Cn1nnc(n1)c1onc(c1)N1CCC(CC1)Oc1cc(F)ccc1Br
- InChi: 1S/C17H16BrFN6O4/c18-12-2-1-10(19)7-13(12)28-11-3-5-24(6-4-11)15-8-14(29-22-15)17-20-23-25(21-17)9-16(26)27/h1-2,7-8,11H,3-6,9H2,(H,26,27)
- InChiKey: UJEAABFSXKCSGI-UHFFFAOYSA-N
Network
Hover on a compound node to display the structore
Synonyms
No synonyms found for this compound
Targets
Known targets for this compound
| Species | Target name | Source | Bibliographic reference |
|---|---|---|---|
| Rattus norvegicus | Acyl-CoA desaturase 1 | Starlite/ChEMBL | References |
| Homo sapiens | stearoyl-CoA desaturase (delta-9-desaturase) | Starlite/ChEMBL | References |
| Mus musculus | stearoyl-Coenzyme A desaturase 1 | Starlite/ChEMBL | References |
Predicted pathogen targets for this compound
By orthology
By sequence similarity to non orthologous known druggable targets
| Species | Potential target | Known druggable target | Length | Alignment span | Identity |
|---|---|---|---|---|---|
| Candida albicans | one of two potential fatty acid desaturase genes similar to S. cerevisiae OLE1 (YGL055W) delta-9 fatty acid desaturase | Acyl-CoA desaturase 1 | 358 aa | 317 aa | 27.1 % |
| Candida albicans | one of two potential fatty acid desaturase genes similar to S. cerevisiae OLE1 (YGL055W) delta-9 fatty acid desaturase | Acyl-CoA desaturase 1 | 358 aa | 317 aa | 27.1 % |
Obtained from network model
Ranking Plot
Putative Targets List
| Species | Potential target | Raw | Global | Species |
|---|---|---|---|---|
| Onchocerca volvulus | 0.0309 | 1 | 0.5 | |
| Plasmodium falciparum | stearoyl-CoA desaturase | 0.0273 | 0 | 0.5 |
| Brugia malayi | acyl-CoA desaturase | 0.0273 | 0 | 0.5 |
| Plasmodium vivax | stearoyl-CoA desaturase (acyl-CoA desaturase, faty acid desaturase), putative | 0.0273 | 0 | 0.5 |
| Onchocerca volvulus | 0.0309 | 1 | 0.5 | |
| Leishmania major | fatty-acid desaturase, putative | 0.0309 | 1 | 0.5 |
| Loa Loa (eye worm) | acyl-CoA desaturase | 0.0273 | 0 | 0.5 |
| Trypanosoma brucei | fatty acid desaturase, putative | 0.0309 | 1 | 0.5 |
| Trypanosoma cruzi | fatty acid desaturase, putative | 0.0309 | 1 | 1 |
Activities
| Activity type | Activity value | Assay description | Source | Reference |
|---|---|---|---|---|
| Activity (binding) | Transport by human OATP1B3 stably transfected in butyrate treated dog MDCK2 cells at 10 uM after 3 hrs by scintillation counting in presence of 100 uM OATP inhibitor sulfobromophthalein | ChEMBL. | 21661758 | |
| Activity (binding) | Transport mediated by human OATP1B1 butyrate treated stably transfected in dog MDCK2 cells at 10 uM after 3 hrs by scintillation counting | ChEMBL. | 21661758 | |
| Activity (binding) | Transport by human OATP1B1 stably transfected in butyrate treated dog MDCK2 cells at 10 uM after 3 hrs by scintillation counting in presence of 100 uM OATP inhibitor sulfobromophthalein | ChEMBL. | 21661758 | |
| Activity (binding) | Transport mediated by human OATP1B3 stably transfected in butyrate treated dog MDCK2 cells at 10 uM after 3 hrs by scintillation counting | ChEMBL. | 21661758 | |
| Cp (ADMET) | = 0.33 uM | Drug uptake in mouse plasma at 10 mg/kg, po after 6 hrs | ChEMBL. | 22101133 |
| Drug uptake (ADMET) | = 0.03 uM | Drug level in plasma of C57BL/6 mouse at 10 mg/kg, po measured 6 hrs post dosing | ChEMBL. | 22209206 |
| Drug uptake (ADMET) | = 0.07 uM | Drug uptake in mouse shaved skin at 10 mg/kg, po after 6 hrs | ChEMBL. | 22101133 |
| Drug uptake (ADMET) | = 1.6 uM | Drug uptake in mouse liver at 0.4 mg/kg, po after 3 hrs | ChEMBL. | 22101133 |
| Drug uptake (ADMET) | = 2.7 uM | Drug level in liver of C57BL/6 mouse at 10 mg/kg, po measured 6 hrs post dosing | ChEMBL. | 22209206 |
| Drug uptake (ADMET) | = 2.7 uM | Drug uptake in mouse liver at 10 mg/kg, po after 6 hrs | ChEMBL. | 22101133 |
| Drug uptake (ADMET) | = 4.9 uM | Drug uptake in mouse liver at 2 mg/kg, po measured after 3 hrs | ChEMBL. | 22101133 |
| ED50 (functional) | = 1 mg kg-1 | Antidiabetic activity in po dosed C57BL/6 mouse LPD model assessed as reduction in liver SCD activity measured 6 hrs post dosing | ChEMBL. | 22209206 |
| F (ADMET) | = 12 % | Oral bioavailability in mouse | ChEMBL. | 21661758 |
| IC50 (binding) | = 1 nM | Inhibition of human SCD-1 | ChEMBL. | 21661758 |
| IC50 (binding) | = 3 nM | Inhibition of mouse SCD-1 | ChEMBL. | 22209206 |
| IC50 (binding) | = 3 nM | Inhibition of SCD-1 activity in Sprague-Dawley rat microsome assessed as reduction in [I-14C] stearoyl CoA desaturation by scintillation counting | ChEMBL. | 21661758 |
| IC50 (binding) | = 3 nM | Inhibition of rat SCD-1 | ChEMBL. | 21661758 |
| IC50 (binding) | = 3 nM | Inhibition of mouse SCD-1 | ChEMBL. | 21661758 |
| IC50 (binding) | = 5 nM | Inhibition of SCD-1 activity in human Hepatocytes expressing organic anion transporting polypeptides assessed as reduction in [I-14C] stearoyl CoA desaturation after 1 hr by scintillation counting | ChEMBL. | 21661758 |
| IC50 (binding) | = 68 nM | Inhibition of SCD1 in rat hepatocytes expressing OATP | ChEMBL. | 22101133 |
| IC50 (binding) | = 68 nM | Inhibition of SCD-1 activity in Sprague-Dawley rat Hepatocytes expressing organic anion transporting polypeptides assessed as reduction in [I-14C] stearoyl CoA desaturation by scintillation counting | ChEMBL. | 21661758 |
| IC50 (binding) | = 1066 nM | Inhibition of SCD-1 activity in organic anion transporting polypeptides-deficient human HepG2 cells assessed as reduction in [I-14C] stearoyl CoA desaturation by scintillation counting | ChEMBL. | 21661758 |
| IC50 (binding) | = 1070 nM | Inhibition of SCD1 in OATP-deficient human HepG2 cells by whole cell assay | ChEMBL. | 22101133 |
| IC50 (binding) | > 100000 uM | Inhibition of rat delta-6 desaturase activity expressed in human HEpG2 cells | ChEMBL. | 21661758 |
| IC50 (binding) | > 100000 uM | Inhibition of human delta6 desaturase activity expressed in human HEpG2 cells | ChEMBL. | 21661758 |
| IC50 (binding) | > 100000 uM | Inhibition of rat delta-5 desaturase activity expressed in human HEpG2 cells | ChEMBL. | 21661758 |
| IC50 (binding) | > 100000 uM | Inhibition of human delta-5 desaturase activity expressed in human HEpG2 cells | ChEMBL. | 21661758 |
| Inhibition (functional) | = 49 % | Antidiabetic activity in C57BL/6 mouse LPD model assessed as reduction in liver SCD activity at 1.6 uM liver concentration dosed at 0.4 mg/kg, po measured 3 hrs post dosing | ChEMBL. | 22209206 |
| Inhibition (functional) | = 49 % | Inhibition of SCD1 in mouse liver assessed as reduction in conversion of [14C]stearic acid to [14C]oleic acid after at 0.4 mg/kg, po after 3 hrs | ChEMBL. | 22101133 |
| Inhibition (functional) | = 89 % | Antidiabetic activity in C57BL/6 mouse LPD model assessed as reduction in liver SCD activity at 4.9 uM liver concentration dosed at 2 mg/kg, po measured 3 hrs post dosing | ChEMBL. | 22209206 |
| Inhibition (functional) | = 89 % | Inhibition of SCD1 in mouse liver assessed as reduction in conversion of [14C]stearic acid to [14C]oleic acid at 2 mg/kg, po measured after 3 hrs | ChEMBL. | 22101133 |
Phenotypes
Whole-cell/tissue/organism interactions
We have no records of whole-cell/tissue assays done with this compound
What does this mean?
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
Annotated phenotypes:
We have no manually annotated phenotypes for this drug.
What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by
drugs, or by genetic manipulation of cells (e.g. gene knockouts or
knockdowns) is manually curated from the literature. These
descriptions help to describe the potential of the target for drug
development. If no information is available for this gene or if the
information is incomplete, this may mean that i) the papers
containing this information either appeared after the curation
effort for this organism was carried out or they were inadvertently
missed by curators; or that ii) the curation effort for this
organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
External resources for this compound
- ChEMBL: CHEMBL1938870
Bibliographic References
3 literature references were collected for this gene.
If you have references for this compound, please enter them in a user comment (below) or Contact us.